Non-operative breast pathology: columnar cell lesions

S E Pinder and J S Reis-Filho

*J. Clin. Pathol.*, 2007;60:1307-1312; originally published online 20 Dec 2006; doi:10.1136/jcp.2006.040634

Updated information and services can be found at:
http://jcp.bmj.com/cgi/content/full/60/12/1307

**References**

This article cites 29 articles, 4 of which can be accessed free at:
http://jcp.bmj.com/cgi/content/full/60/12/1307#BIBL

1 online articles that cite this article can be accessed at:
http://jcp.bmj.com/cgi/content/full/60/12/1307#otherarticles

**Rapid responses**

You can respond to this article at:
http://jcp.bmj.com/cgi/eletter-submit/60/12/1307

**Email alerting service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Notes**

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to *Journal of Clinical Pathology* go to:
http://journals.bmj.com/subscriptions/
Non-operative breast pathology: columnar cell lesions

S E Pinder, J S Reis-Filho

The term “columnar cell lesions” encompasses a spectrum of processes, characterised by variably dilated acini, lined by one to several layers of tightly packed, columnar-shaped epithelial cells. These lesions have received renewed attention in the literature due to their high prevalence in biopsy specimens taken for assessment of mammographically detected microcalcification. In addition, increasing interest has been directed at the sub-set of columnar cell lesions with varying degrees of cytological atypia. Recent observational and molecular genetic studies have provided strong circumstantial evidence to suggest that at least some of these lesions may represent the earliest morphologically identifiable, non-obligate precursor of low grade breast carcinomas. However, the risk of both local recurrence and progression to invasive cancer appears to be exceedingly low. This review provides an update on recent clinicopathological and molecular data on columnar cell lesions and how these have changed our perception of, and the classification system for, these lesions. In addition, guidelines for the management of patients with columnar cell lesions diagnosed in core needle biopsy specimens are provided.

Columnar cell lesions in the breast have been recognised by histopathologists for a long period of time, but under a wide variety of names such as blunt duct adenosis, clinging carcinoma of monomorphic type, columnar alteration with prominent apical snouts and secretions, atypical cystic lobules, enlarged lobular units with columnar alteration and hyperplastic unfolded lobules, among others. This lack of clarity in nomenclature makes interpretation of the medical literature difficult with regard to incidence, behaviour and significance of these lesions. However, it is clear that such lesions are being seen more frequently as a result of breast screening mammography; they frequently present with, often low suspicion, microcalcifications on breast mammography and are, as a result, an increasingly common finding in non-operative breast core samples. Indeed, columnar alterations were reported in 42% of 100 consecutive biopsy specifications for microcalcifications in one of the early seminal papers on these lesions. Specifically, the calcification was present within the columnar process itself in 74% of cases; these lesions are generally a direct cause of the radiological findings, not a coincidental histological finding.

The term “columnar cell lesions” is now widely used and incorporates a family of entities. The spectrum ranges from columnar cell change and columnar cell hyperplasia, through cytologically low grade but atypical lesions (flat epithelial atypia), architecturally complex lesions (now regarded as forms of atypical ductal hyperplasia (ADH), or indeed low grade ductal carcinoma in situ (DCIS) if more extensive). At the upper end of the spectrum one might include flat high grade DCIS, although the latter is not generally included in this group of entities. It should be noted that many columnar cell lesions in breast core biopsy samples cause no significant diagnostic difficulty. However, there is a small, but important sub-group, that shows either histological or architectural atypia and which can be problematic for the pathologist regarding diagnosis and classification, and the whole multidisciplinary team with respect to clinical behaviour and management. Such lesions can be especially difficult to interpret in core samples, due to the partial sampling of lesions inherent in the biopsy technique.

Microscopy of columnar cell lesions

Table 1 summarises features which assist in distinguishing the forms of columnar cell lesion and ADH. It is useful to remember that columnar cell changes arise in the terminal duct lobular unit (TDLU), and in surgical specimens the low power assessment of the overall architecture and geographical nature is valuable (fig 1). This may not be assessable in core biopsy specimens, which include only small portions of tissue. At a higher power examination, columnar cell change can be seen to be formed from a single or a double layer of columnar cells that are of regular size and shape with relatively bland nuclear features and which are arranged perpendicular to the basement membrane. The nuclei are uniform, typically ovoid, with finely dispersed chromatin and do not bear conspicuous nucleoli. Mitoses are not generally seen. Secretions and calcifications are often present in the lumen and apical snouts are noted at the luminal aspect of the cells.

The morphology of the cells forming columnar cell hyperplasia is essentially similar to those of columnar cell change (figs 2 and 3). Rather than a single or double layer of cells, however, there is focal stratification; mounds or tufts of epithelial cells are often formed. True micropapillae (with bulbous tip extending into the lumen from a narrower stalk) or sieve-like cribriform spaces are not a feature of columnar cell hyperplasia but should make one search for additional features of ADH/DCIS. There may, however, be some nuclear crowding and/or overlapping of nuclei in columnar cell hyperplasia. This should not be mistaken for an atypical proliferative process; of note, low grade neoplastic processes in the breast (ADH, DCIS and lobular in situ neoplasia) are typically formed from evenly-spaced, regular, uniform cells. In columnar...
cell hyperplasia more overlapping and variation of cells is seen, although this is not as marked as in usual epithelial hyperplasia, which is truly formed from cells of a mixed phenotype. Apical snouts are often prominent in columnar cell hyperplasia and there is frequently abundant intraluminal secretion with microcalcification.

Superimposed on the columnar cell morphology of the one or two layers of epithelial cells of columnar cell change or the stratified layering of columnar cell hyperplasia, there may be atypia. In previous systems of classification this was subdivided into architectural or cytological types. Subsequently, the World Health Organization Working Group on the Pathology and Genetics of Tumours of the Breast applied the term flat epithelial atypia (FEA) for columnar cell lesions with cytological atypia. That this term encompasses both columnar cell change and columnar cell hyperplasia, with cytological atypia, is somewhat counterintuitive; it should be noted that flat epithelial atypia is not necessarily “flat”, but rather does not form complex architectural patterns such as cribriform spaces or micropapillae. Those lesions previously categorised as columnar cell hyperplasia with architectural atypia, due to the presence of bridges or micropapillary structures formed from epithelial cells showing mild cytonuclear atypia, are now classified within the spectrum of ADH (fig 4) or low grade DCIS. This latter categorisation depends, as in other situations, on the nature and the extent of the cytological and architectural atypia.

The TDLUs bearing FEA have been described as typically having a rounded luminal shape, rather than an irregular internal outline as is seen in columnar cell changes without atypia; this feature may be valuable on low power examination of the section. Similarly, at low power examination the TDLUs bearing FEA may be darker appearing than usual, due to an increased nuclear to cytoplasmic ratio of the characteristic cells. In addition, on occasions visible on low power, a lymphoid infiltrate formed from collections of mature lymphoid cells may be present in the stroma associated with, and adjacent to, the FEA.

On higher power examination, FEA is most commonly formed from cuboidal cells with features of low grade DCIS; thus nuclei are round, small, uniform and evenly-spaced (fig 5). The chromatin pattern is finely dispersed. Nucleoli tend not to be conspicuous and mitoses are rarely seen. Apical snouts are commonly present and secretions with microcalcification noted. This form of FEA may be subtle and care should be taken not to overlook the lesion in breast histology specimens.

In other forms within the category of FEA, the cells retain more of an overt columnar morphology, and thus may be more elongated and polarised, with nuclei arranged perpendicular to the basement membrane. However, in addition to these architectural features of columnar cell change or hyperplasia, the cells also show cytologically atypical features, of more “classical” type, including cytological pleomorphism, clumping of chromatin and distinct nucleoli. The nuclei may, in essence, be essentially similar to those nuclei seen typically in tubular carcinomas with a more obvious increase in nuclear to cytoplasmic ratio (fig 6) than seen in the form of flat epithelial atypia with round, uniform, evenly spaced nuclei, described above. Less commonly, the nuclei may show a superficial resemblance to the cytology of colorectal adenomas.

In core biopsy specimens in particular, cytological atypia in columnar cell change may be difficult to assess and a tightrope must be balanced between over-diagnosis (and an excessively high benign biopsy rate in subsequent surgical diagnostic biopsy) and reporting as atypial any lesions of concern.

---

Table 1 Differential diagnosis of columnar cell change, columnar cell hyperplasia, flat epithelial atypia and atypical ductal hyperplasia

<table>
<thead>
<tr>
<th>Feature</th>
<th>CCC</th>
<th>CCH</th>
<th>FEA</th>
<th>ADH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell morphology</td>
<td>Columnar</td>
<td>Columnar</td>
<td>Columnar and/or cuboidal</td>
<td>Cuboidal</td>
</tr>
<tr>
<td>Number of cell layers ≤ 2</td>
<td>Flat</td>
<td>≥2 Tufts/mounds</td>
<td>Flat or tufts/mounds. Not complex*</td>
<td>Variable</td>
</tr>
<tr>
<td>Architecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuclear atypia†</td>
<td>Absent</td>
<td>Absent</td>
<td>Present</td>
<td>Present</td>
</tr>
<tr>
<td>Nuclear features†</td>
<td>Ovoid, bland, polarised nuclei arranged perpendicular to basement membrane</td>
<td>Ovoid, bland; some nuclear crowding and overlapping of nuclei may be observed. Nuclei arranged perpendicular to basement membrane</td>
<td>In typical form: round, uniform, evenly-spaced with finely dispersed chromatin, as in low grade DCIS. Alternatively may show more “classical” cytonuclear atypia in the form of enlarged, more oval nuclei with mild to moderate pleomorphism; some clumping of chromatin may be seen</td>
<td>Round and evenly spaced as in low grade DCIS; finely dispersed chromatin</td>
</tr>
<tr>
<td>Nuclear to cytoplasmic ratio</td>
<td>Normal</td>
<td>Normal</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Internal contours of acini</td>
<td>Irregular</td>
<td>Irregular</td>
<td>Typically smooth</td>
<td>Variable</td>
</tr>
</tbody>
</table>

ADH, atypical ductal hyperplasia; CCC, columnar cell change; CCH, columnar cell hyperplasia; FEA, flat epithelial atypia; DCIS, ductal carcinoma in situ.
†True micropapillae (with bulbous tip extending into the lumen from a narrower stalk) or sieve-like cribriform spaces.
†Cases with high grade nuclear atypia should be classified as flat high grade DCIS and do not fall within either the spectrum of FEA or of ADH.
It should be remembered, however, if the cytonuclear features are those of high grade atypia, for example, formed from large cells showing marked pleomorphism and nuclear atypia, then the disease should be categorised as flat high grade DCIS and not as FEA. This too may be difficult to assess and caution is advised not to “over-call” lesions with moderate atypia as flat high grade DCIS in core biopsy; in such cases prudence should be applied, and on occasions the suspicious (B4) category can be used (fig 7).

DIFFERENTIAL DIAGNOSIS

The differential diagnosis of columnar cells lesion includes apocrine metaplasia and other fibrocystic changes, such as small benign cysts. Careful examination of the cytological features of the epithelium should be undertaken to avoid missing the diagnosis of FEA in particular, which can be subtle and which can be overlooked completely or misinterpreted as microcysts. Both apocrine change and columnar cell lesions arise in the TDLU and although both have apical snouts, morphological assessment will show the granular, eosinophilic cytoplasm with inclusions in apocrine change. The nuclei of apocrine cells are also typically larger, have one or more prominent nucleoli, and may show some variation in size; the nuclei of columnar cell change are blander, more uniform and lack prominent nucleoli.

Unfortunately additional and special stains are, in general, of little assistance in the assessment and diagnosis of columnar cell lesions, with or without atypia. The cells of the columnar cell processes typically express luminal cytokeratins, such as cytokeratin 19, and both oestrogen and progesterone receptors. In particular, the pattern of oestrogen receptor staining in columnar cell change is typically diffusely positive when compared to heterogeneous positivity of usual epithelial hyperplasia and normal breast lobules. Conversely, columnar cell lesions do not express basal markers such as cytokeratin 5/6. In cases when the there is uncertainty in distinguishing columnar cell change from apocrine change, immunohistochemistry may prove helpful as columnar cells invariable express oestrogen receptor and also bcl-2, while apocrine cells typically express gross cystic disease fluid protein 15 but are negative for bcl-2 and oestrogen receptor.

MOLECULAR AND GENETIC STUDIES AND CLINICAL STUDIES OF COLUMNAR CELL LESIONS

The clinical significance of the columnar cell lesions remains poorly understood. Although this is in part due to the difficulties in interpretation of the medical literature due to the nomenclature used, as noted above, such lesions have recently been studied in small numbers and in few observational series. Flat epithelial atypia is more frequently identified in association with established DCIS than one would see purely by chance. Columnar cell lesions, in particular those with nuclear atypia, may also co-exist with lobular in situ neoplasia (fig 8). Observational studies have, in addition, noted a relationship with tubular carcinoma, and Rosen suggested some years ago that that tubular carcinoma “might sometimes arise when the hyperplastic lesion transformed”.

Apart from this, somewhat circumstantial, evidence and opinion, robust data on the clinical behaviour of these lesions is very scare; Eusebi et al found 25 cases of monomorphic/low grade “clinging” carcinoma from 80 cases of DCIS out of a total of 9446 biopsy specimens originally diagnosed as benign. However, only one of the 25 cases developed a so-called recurrence, at a mean follow up of 17.5 years, and this as the same “clinging” carcinoma, which would now be classified as...
FEA. Importantly, no cases developed invasive disease. Similarly, in the EORTC 10853 DCIS trial, 59 patients with low grade “clinging” carcinoma were noted; with a median follow-up of 5.4 years, no local recurrences have been reported. De Mascarel et al. have reported in abstract form on 115 patients with columnar cell hyperplasia with atypia, 45 of who had had radiotherapy; they identified three cases of subsequent invasive carcinoma, one case of DCIS in the contralateral breast and three “recurrences” of FEA. Thus, overall, authorities on the subject suggest that the risk of patients developing invasive breast carcinoma in the same breast as an index case of FEA is very low, albeit based on the limited date available to date regarding the precursor risk of columnar cell lesions.

Small series examining the molecular and genetic changes in atypical columnar cell lesions have begun to appear in the medical literature; the numbers in many of these are small. Moinfar et al. noted a high level (77%) of loss of heterozygosity (LOH), most commonly at 11q, 16q and 3p. Eighteen cases were associated with DCIS or invasive carcinoma, in which similar genetic changes were present. Similarly, Simpson et al. found changes in FEA and in associated columnar cell change and columnar cell hyperplasia using comparative genomic hybridisation. In five of eight cases, there were also similar abnormalities in associated DCIS or invasive carcinoma, suggesting an evolutionary spectrum. The genetic changes were few in number, but recurrent losses (eg, of 16q, 17p) and gains (eg, of 16p) were present across the spectrum of 81 lesions from 18 patients. Interestingly, the degree of hyperplasia and atypia at the morphological level was associated with a stepwise increase in the number of unbalanced chromosomal changes at the molecular level. Several of the reported series to date have thus examined somewhat biased groups of columnar cell lesions that have included, in the same patients, a range of abnormalities through to DCIS and invasive carcinoma. Very few cases of the commoner and less worrisome end of the spectrum that are not associated with more advanced disease in the same breast have been examined. Dabbs et al. reported that neither of two examples of pure columnar cell change showed abnormalities with LOH assessment, but losses at one or more loci were present in two of three cases of columnar cell hyperplasia and in two-thirds of the 15 cases of FEA. However, the most frequent loci reported to be affected in CCL/FEA, 16q and 11q, in other series, were not analysed in that study. As in the other molecular studies described, some of the genetic alterations in the columnar cell lesions in this study were similar to those in associated DCIS and invasive carcinoma. Thus, at least a proportion of columnar cell lesions almost certainly represents the earliest form of precursor of low grade DCIS and of invasive breast carcinoma recognised to date. Interestingly, the idea that columnar cell changes could be the earliest morphologically identifiable precursor of breast cancer was first put forward in British literature by Muir, in 1941, who suggested that in the evolution of breast cancer, the “earliest change to be observed in the epithelium of the acini is an increased prominence of the cells; they become...often of more columnar type; sometimes this is a marked feature.”

MANAGEMENT OF COLUMNAR CELL LESIONS IN BREAST CORE BIOPSY SPECIMENS

Despite the emerging molecular information regarding the neoplastic and precursor nature of, at least a subset of, columnar cell lesions, the management of these lesions is also...
Columnar cell lesions are frequently seen as a cause of mammographic microcalcification.

- The majority are benign (B2), but a minority show low grade cytological atypia (flat epithelial atypia) and should be reported as B3 on core biopsy.

- There is emerging evidence that such low grade atypical columnar cell lesions are the earliest non-obligate precursors of breast cancer, to date.

- If architectural atypia is also present, the lesion should be reported as atypical ductal hyperplasia or low grade ductal carcinoma in situ, according to extent.

CONCLUSION

In conclusion, columnar cell lesions are being identified with increasing frequency in breast core biopsy specimens undertaken for the assessment of mammographic microcalcifications, often of low radiological suspicion. Although the majority of these lesions do not cause significant diagnostic difficulty, a sub-group of these lesions shows atypical histological features; these should be classified as B3, lesion of uncertain malignant potential, on core biopsy. Such atypical columnar cell lesions remain poorly understood, but small studies have begun to describe the molecular and clinical findings in these lesions. Although there are still very limited data, these suggest that FEA may be the earliest morphologically identifiable non-obligate precursor of low grade breast carcinomas. The true precursor risk appears very low, but these lesions may co-exist with entities such as low grade DCIS and low grade invasive carcinoma. Thus when FEA is identified in a breast core biopsy specimen, at present it is recommended that diagnostic surgical excision should be undertaken to search for more established adjacent malignant disease.

Authors’ affiliations
S E Pinder, Department of Histopathology, Addenbrooke’s Hospital, Cambridge, UK
J S Reis-Filho, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK

Competing interests: None declared.

REFERENCES


27 Nasser S, Fan MJ. Does atypical columnar cell hyperplasia on breast core biopsy warrant follow-up excision? Mod Pathol 2003; 16:42A.

28 Konju LP, Kleer CG. Significance of flat epithelial atypia (FEA) on mammotome core needle biopsy: should it be excised? Lab Invest 2006; 86:32A.


31 Xu C, Chung A, Giri D. Diagnosis of columnar cell change with atypia on breast core biopsy: impact of inter-observer variability, degree of atypia and the volume of lesional changes on surgical management. Lab Invest 2005; 85:55A.


---

**BMJ Clinical Evidence—Call for contributors**

**BMJ Clinical Evidence** is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. **BMJ Clinical Evidence** needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

**Areas for which we are currently seeking contributors:**
- Secondary prevention of ischaemic cardiac events
- Acute myocardial infarction
- MRSA (treatment)
- Bacterial conjunctivitis

However, we are always looking for contributors, so do not let this list discourage you.

**Being a contributor involves:**
- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with **BMJ Clinical Evidence** editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The **BMJ Clinical Evidence** in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- To expand the review to include a new question about once every 12 months. In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for **BMJ Clinical Evidence** or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

**Call for peer reviewers**

**BMJ Clinical Evidence** also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge).

Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to **BMJ Clinical Evidence** for 3 months for each review.

If you are interested in becoming a peer reviewer for **BMJ Clinical Evidence**, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp